ReviewFrontiers in immunology2026

The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer.

Mingyao Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.